• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO CARDIOVASCULAR SYSTEMS CORPORATION NS FX25REC W/RES; BLOOD GAS OXYGENATOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO CARDIOVASCULAR SYSTEMS CORPORATION NS FX25REC W/RES; BLOOD GAS OXYGENATOR Back to Search Results
Model Number 3ZZ*FX25RECA
Device Problem High Readings (2459)
Patient Problems Insufficient Information (4580); No Clinical Signs, Symptoms or Conditions (4582)
Event Date 08/18/2022
Event Type  malfunction  
Manufacturer Narrative
Terumo has received the device for evaluation; however, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.(b)(4).
 
Event Description
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the potassium levels shot up to over 7.3.It is unknown if the product malfunction cause or contribute to an injury.Terumo continues to attempt to gain more information regarding this event from the user facility.As per user facility, "ccp went on bypass and potassium levels shot up to over 7.3.Before bypass potassium levels were at 4.3.After bypass potassium levels went back down to 4.0.Ccp's thought maybe there was an increase in potassium levels because of a water leak in the oxy.There was no noticeable increase in volume in the reservoir during bypass and post bypass there was no known increase in hemolysis after.Ccp's would like our lab to check and see if there was a leak in the heat exchanger.*product was not changed out.*procedure completed successfully.
 
Manufacturer Narrative
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on september 8, 2022.Upon further investigation of the reported event, the following information is new and/or changed: g6 (indication that this is a follow-up report).H2 (follow-up due to correction and additional information).H6 (adverse event problem 2199, 4582, 11).A second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.).All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
 
Event Description
New information received.The product did not malfunction cause or contribute to an injury.
 
Manufacturer Narrative
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: h6 (identification of evaluation codes 10, 3331, 213, 67) type of investigation #1: 10 - testing of actual/suspected device type of investigation #2: 3331 - analysis of production records investigation findings: 213 - no device problem found investigation conclusions: 67 - no problem detected the returned sample was found to have no visual anomalies upon receipt.After being rinsed and dried, the heat exchanger of the sample was filled with colored water, the water outlet port was blocked, and air pressure of 3kgf/cm2 was applied to the water channel form the water inlet port, with no leakage observed.The blood channel was then filled with colored saline solution, the blood outlet port was blocked and air pressure of 2kgf/cm2 was applied to the blood channel from the blood inlet port.No leakage was observed.The evaluation of the returned sample was found to have no anomalies leading to leakage after cleaning.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
NS FX25REC W/RES
Type of Device
BLOOD GAS OXYGENATOR
Manufacturer (Section D)
TERUMO CARDIOVASCULAR SYSTEMS CORPORATION
125 blue ball road
elkton MD 21921
Manufacturer (Section G)
SAME
Manufacturer Contact
jamie quinlan
125 blue ball road
elkton, MD 21921
8002837866
MDR Report Key15378988
MDR Text Key306003986
Report Number1124841-2022-00150
Device Sequence Number1
Product Code DTZ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K151791
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,User Facility,Company Representative
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup,Followup
Report Date 10/24/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/08/2022
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model Number3ZZ*FX25RECA
Device Catalogue NumberN/A
Device Lot Number2G20
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer08/25/2022
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received10/20/2022
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured06/20/2022
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
-
-